Drugs / Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells

Follow last change Mar 2022 re-read 3 minutes ago

Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells

Developed for: acute respiratory distress syndrome
Investigated by: Immune Tolerance Network (ITN) · Jeffrey Bluestone · National Institute of Allergy and Infectious Diseases (NIAID)

today NCT05027815 · Ph 1

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05027815	Sep 2021 → Mar 2022	acute respiratory distress syndrome	Jeffrey Bluestone	Terminated	No outcome recorded Stop: Enrollment

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05027815 ↗
Modality	Cell therapy	“cryopreserved cellular therapy product” NCT05027815 ↗
Route	Intravenous	“for IV infusion” NCT05027815 ↗